for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sarepta Therapeutics Inc

SRPT.O

Latest Trade

83.48USD

Change

0.32(+0.38%)

Volume

885,428

Today's Range

82.69

 - 

85.12

52 Week Range

72.05

 - 

158.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
83.16
Open
83.94
Volume
885,428
3M AVG Volume
36.87
Today's High
85.12
Today's Low
82.69
52 Week High
158.80
52 Week Low
72.05
Shares Out (MIL)
74.34
Market Cap (MIL)
6,205.94
Forward P/E
-11.16
Dividend (Yield %)
--

Next Event

Q3 2019 Sarepta Therapeutics Inc Earnings Release

Latest Developments

More

Sarepta Therapeutics Announces Positive Functional Results From SRP-9003 (Myo-101) Gene Therapy Trial To Treat Limb-Girdle Muscular Dystrophy Type 2E, Or Beta-Sarcoglycanopathy

Sarepta Therapeutics Receives Complete Response Letter From The U.S. Food And Drug Administration For Golodirsen New Drug Application

Sarepta Therapeutics Comments On Erroneous Submission To Us FDA Adverse Event Reporting System

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry

Biotechnology & Drugs

Contact Info

215 1st St Ste 415

+1.617.2744000

https://www.sarepta.com/

Executive Leadership

M. Kathleen Behrens

Independent Chairwoman of the Board

Douglas S. Ingram

President, Chief Executive Officer, Director

Sandesh Mahatme

Executive Vice President, Chief Financial Officer and Chief Business Officer

David Tyronne Howton

Executive Vice President, General Counsel, Secretary

Alexander Cumbo

Executive Vice President and Chief Commercial Officer

Key Stats

1.70 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.2K

2018

0.3K

2019(E)

0.4K
EPS (USD)

2016

-4.740

2017

-0.860

2018

-5.460

2019(E)

-7.272
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.01
Price To Book (MRQ)
5.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
39.22
LT Debt To Equity (MRQ)
39.22
Return on Investment (TTM)
-41.81
Return on Equity (TTM)
-38.09

Latest News

Latest News

Sarepta shares sink 14% after shock FDA rejection

Shares of Sarepta Therapeutics Inc plunged 14% on Tuesday after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

Sarepta shares sink 17% after shock FDA rejection

Shares of Sarepta Therapeutics Inc plummeted 17% on Tuesday after the U.S. health regulator, in a surprise move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

FDA declines to approve Sarepta's second Duchenne treatment

Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

U.S. FDA declines to approve Sarepta's second Duchenne drug

The U.S. Food and Drug Administration declined to approve Sarepta Therapeutics Inc's newest treatment for Duchenne muscular dystrophy (DMD), a rare muscle-wasting disorder that mainly affects boys, the company said on Monday.

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc <SRPT.O> said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD).

Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy was reported to have developed a serious illness.

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc <SRPT.O> surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc <PFE.N>.

Sarepta shares rise after gene therapy deal, promising data

Sarepta Therapeutics Inc beefed up its gene therapies portfolio through the purchase of its partner Myonexus Therapeutics Inc and reported positive data for a genetic disorder therapy from the privately held company, sending its shares up 9 percent on Wednesday.

Sarepta to buy gene therapy developer Myonexus for $165 mln

Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Sarepta shares soar as Duchenne gene therapy shows promise

Sarepta Therapeutics' shares jumped 60 percent on Tuesday after promising results from a gene therapy study positioned the specialty drugmaker as a potential leader in the market for Duchenne muscular dystrophy (DMD) treatments.

BRIEF-Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

* SAREPTA AND INVITAE EXPAND PARTNERSHIP TO ADVANCE CLINICAL RESEARCH IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

BRIEF-Sarepta Therapeutics Reports Q1 Loss Per Share Of $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Sarepta Therapeutics Announces Partnership With Myonexus Therapeutics

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH MYONEXUS THERAPEUTICS FOR THE ADVANCEMENT OF MULTIPLE GENE THERAPY PROGRAMS AIMED AT TREATING DISTINCT FORMS OF LIMB-GIRDLE MUSCULAR DYSTROPHIES

BRIEF-Sarepta Therapeutics Inc Says CEO Douglas Ingram's 2017 Total Compensation Was $56.9 Million

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2017 TOTAL COMPENSATION WAS $56.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2I3lSGe) Further company coverage:

Sarepta Therapeutics beats bid to revive shareholder class action

A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics

* CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING Source text: (http://bit.ly/2kzjwV3) Further company coverage:

Sarepta Therapeutics investors seek revival of fraud lawsuit

A lawyer for Sarepta Therapeutics Inc shareholders urged a federal appeals court on Monday to revive a lawsuit claiming the company misled investors about whether it had gathered enough data to seek Food and Drug Administration approval for a treatment for a rare muscle...

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up